The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways

The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways

Summary: The glucagon-like peptide-1 receptor agonists (GLP-1RAs) liraglutide and semaglutide reduce cardiovascular risk in type 2 diabetes patients. The mode of action is suggested to occur through modified atherosclerotic progression. In this study, both of the compounds significantly attenuated p...

Full description

Bibliographic Details
Main Authors: Günaj Rakipovski, PhD, Bidda Rolin, DVM, Jane Nøhr, PhD, Ib Klewe, PhD, Klaus S. Frederiksen, PhD, Robert Augustin, PhD, Jacob Hecksher-Sørensen, PhD, Camilla Ingvorsen, PhD, Joseph Polex-Wolf, PhD, Lotte Bjerre Knudsen, DMSc
Format: Article
Language:English
Published: Elsevier 2018-12-01
Series:JACC: Basic to Translational Science
Online Access:http://www.sciencedirect.com/science/article/pii/S2452302X18302389

Internet

http://www.sciencedirect.com/science/article/pii/S2452302X18302389

Similar Items